摘要
目前,原发性高血压及其并发症仍是影响人类健康的主要疾病之一。原发性高血压因其知晓率低和治疗率低、药物不耐受、患者依从性差以及不合理用药等原因,有近1/3患者不能有效控制血压,处在心脑血管疾病高危状态。为此,寻求更为安全和有效的治疗高血压的方法十分迫切。去肾交感神经支配术基于导管方法应用射频消融选择性靶向损毁肾交感神经,以达到治疗顽固性高血压的目的。有两项临床试验(Symplicity HTN-1和HTN-2)对该技术进行了评估,为其安全性和有效性提供了证据。本文简要介绍这一技术在安全性和有效性方面的最新数据。
Although effective antihypertensive drug together with lifestyle intervention has been widely employed in the medical field, essential hypertension remains one of the main diseases affecting human being＇s health. Because of some reasons such as lower rate of patients＇ awareness of hypertension, lower rate of receiving treatment, poor tolerance to the antihypertensive drugs, patient＇s poor biddable willing, unreasonable medication, etc. about one third of the patients having essential hypertension are not be able to effectively control their blood pressure level and they have been in a high risk status to cardio- cerebral vascular diseases all along. Therefore, it is very urgent to find out a safer and more effective therapy for essential hypertension. Renal sympathetic denervation （RSD） has been recently employed in clinical practice for hypertension. This therapy is based on the catheterization technique combined with the radiofrequency ablation to selectively destroy the targeted renal nerves in order to treat the intractable essential hypertension. Two clinical trials, Symplicity HTN-1 and HTN-2, have been conducted to evaluate the feasibility and effectiveness of RSD, and the results provide reliable evidence, which indicates that RSD is safe and effective in clinical use. This paper aims to make a brief introduction of the recent research progress concerning the safety and efficacy of RSD technique. （J Intervent Radiol, 2012, 21： 441-446）
出处
《介入放射学杂志》
CSCD
北大核心
2012年第6期441-446,共6页
Journal of Interventional Radiology
